Search results for "Biochemistry"

showing 10 items of 20172 documents

Knowledge and attitudes towards smoking cessation counselling: an Italian cross-sectional survey on tertiary care nursing staff

2021

Background One of the most effective smoking cessation strategies involves care and advice from nurses due to their role in the front line of treatment. Lack of education on smoking cessation counselling may be detrimental, and adequate smoking cessation training during healthcare studies is needed. Objectives The study aimed to examine nurses’ attitudes, belief, and knowledge of smoking cessation counselling; knowledge of the health risks associated with smoking was also assessed. Design A cross-sectional survey on 77 nurses from the nursing staff of Cardiology, Cardiac Intensive Care and Surgical Oncology Units of two tertiary hospitals. Methods Cronbach’s alpha was calculated to assess …

medicine.medical_specialtyCross-sectional studymedicine.medical_treatmentNursingSmoking cessationGeneral Biochemistry Genetics and Molecular BiologySettore MED/01 - Statistica MedicaEducationSmoking cessation Counselling Education Training Tobacco-control Quit smokingCronbach's alphaSettore MED/28 - Malattie OdontostomatologicheQuit smokingIntensive careHealth caremedicineTrainingbusiness.industryGeneral NeuroscienceTobacco controlRGeneral MedicineScience and Medical EducationSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheFamily medicineCoronary care unitSmoking cessationMedicineCounsellingPublic HealthGeneral Agricultural and Biological SciencesbusinessInclusion (education)Tobacco-controlPeerJ
researchProduct

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response…

2008

Abstract Introduction: Previous phase II studies have suggested that a combination of FCR may increase the outcome of both untreated and relapsed CLL pts. In order to validate this concept the German CLL study group (GCLLSG) initiated a multicentre, multinational phase III trial, CLL8, to evaluate the efficacy and tolerability of FCR versus FC for the first-line treatment of pts with advanced CLL. Methods and Patients: 817 pts with good physical fitness as defined by a cumulative illness rating scale (CIRS) score (Extermann et al., JCO 1998) of up to 6 and a creatinine clearance (cr cl) □d 70 ml/min were enrolled between July 2003 and March 2006. Pts were randomly assigned to receive 6 cour…

medicine.medical_specialtyCyclophosphamideImmunologychemical and pharmacologic phenomenaNeutropeniaBiochemistryGastroenterology03 medical and health sciences0302 clinical medicineChemoimmunotherapyInternal medicinemedicineProgression-free survivalLeukopeniabusiness.industryCell BiologyHematologymedicine.disease3. Good healthSurgeryFludarabineTolerability030220 oncology & carcinogenesisConcomitantmedicine.symptombusiness030215 immunologymedicine.drugBlood
researchProduct

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

2019

Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is an acute, life-threatening thrombotic microangiopathy that requires urgent and specialized treatment. Prior to the introduction of caplacizumab, the treatment for aTTP was based on daily therapeutic plasma exchange (TPE; to replenish functional ADAMTS13 enzyme) plus immunosuppression (mainly corticosteroids and rituximab; to suppress anti-ADAMTS13 autoantibody production). TPE combined with immunosuppressive therapy improved outcomes in patients; however, episodes of aTTP are still associated with an acute mortality of up to 20% as these therapies do not have an immediate effect on the pathologic microvascular thrombosis. Th…

medicine.medical_specialtyCyclophosphamidebusiness.industryBortezomibmedicine.medical_treatmentImmunologySplenectomyImmunosuppressionHydroxychloroquineCell BiologyHematologyBiochemistryRegimenPharmacotherapyInternal medicinemedicineRituximabbusinessmedicine.drugBlood
researchProduct

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patie…

2009

Abstract Abstract 535 Introduction: In 2008, first results of a multicenter, international randomized phase III trial (CLL8) were presented, showing superiority of FCR chemoimmunotherapy for response rates and progression-free survival (PFS) when compared to FC chemotherapy. We now report updated results with a longer median observation time of 37.7 months (mo). Methods and Patients: 817 treatment-naïve patients (pts) with good physical fitness and CD20-positive CLL randomly (1:1) received treatment with 6 courses of either FCR or FC therapy. Both treatment arms were well balanced with regard to sex, age, stage, genomic aberrations and IGVH gene status. The median age was 61 years (range 3…

medicine.medical_specialtyCyclophosphamidebusiness.industryImmunologyCell BiologyHematologyNeutropeniamedicine.diseaseBiochemistryChemotherapy regimenFludarabinelaw.inventionRandomized controlled triallawChemoimmunotherapyInternal medicinemedicineRituximabbusinessProgressive diseasemedicine.drug
researchProduct

Y-90 Ibritumomab Tiuxetan as Consolidation Following Three Cycles of Fludarabine-Cyclophosphamide-Rituximab Chemoimmunotherapy in Patients with Relap…

2007

Abstract BACKGROUND: Tumed sequential treatment with fludarabine/cyclophosphamide/rituximab (FC-R) followed by Y-90 ibritumomab tiuxetan (IT) radioimmunotherapy may improve progression-free survival in patients (pts) with CD20+ NHL. However, even unpretreated pts submitted to four to six cycles of a fludarabine-containing combination and then IT at an Y-90 activity of 15 MBq/kg will experience severe prolonged, transfusion-dependent and only partially reversible pancytopenia, thus limiting its use in a non-curative setting (Jurczak et al., ASH 2005). AIM: We report on a trial including anthracycline-pretreated pts with relapsing CD20+ lymphoma > age 50 and unsuitable for myeloablative tr…

medicine.medical_specialtyCyclophosphamidebusiness.industrymedicine.medical_treatmentImmunologyIbritumomab tiuxetanCell BiologyHematologyNeutropeniamedicine.diseaseBiochemistryGastroenterologyFludarabineChemoimmunotherapyRadioimmunotherapyInternal medicinemedicineRituximabMantle cell lymphomabusinessmedicine.drugBlood
researchProduct

Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with acute lymphoblastic leukemi…

2014

Abstract Total-body-irradiation (TBI) based preparative regimens are considered as standard conditioning therapy for allogeneic stem cell transplantation (AHSC) in patients with acute lymphoblastic leukemia (ALL). Within a multi-center prospective phase II study we have investigated the toxicity and efficacy of a non-TBI-based regimen consisting of treosulfan, etoposide, and cyclophosphamide in patients with ALL. Inclusion criteria were complete remission, non-eligibility for TBI or patient’s wish to avoid TBI. Between July 2007 and August 2010, 50 patients with a median age of 46.5 years were enrolled at ten German centers. 74% of the patients were in 1. CR and 26% 2. or higher CR.The cond…

medicine.medical_specialtyCyclophosphamidebusiness.industrymedicine.medical_treatmentImmunologyPhases of clinical researchCell BiologyHematologyHematopoietic stem cell transplantationTreosulfanBiochemistrySurgeryTransplantationRegimenInternal medicinemedicineCumulative incidencebusinessEtoposidemedicine.drug
researchProduct

18-hydroxylation in the Y-1 adrenal cell line: response to ACTH and to culture conditions.

1992

The 18-hydroxylation of deoxycorticosterone in the Y-1 adrenal cell line was studied under various incubation and cell culture conditions and compared to 11 beta-hydroxylation. Repeated incubation of the substrate increased both 18- and 11 beta-hydroxylation in the Y-1 cells. Furthermore, both 18- and 11 beta-hydroxylation were increased with increased serum concentration and prolonged incubation time. While the increase in 11 beta-hydroxylation seemed to be independent of the type of serum, 18-hydroxylation was much more important in cells cultured in fetal or newborn calf serum supplemented medium than in those cultured in horse serum supplemented medium. As expected, ACTH treatment incre…

medicine.medical_specialtyCytochromeEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryHydroxylationBiochemistryHydroxylationchemistry.chemical_compoundMiceEndocrinologyAdrenocorticotropic HormoneCytochrome P-450 Enzyme SystemInternal medicineAdrenal GlandsmedicineAnimalsCytochrome P-450 CYP11B2DesoxycorticosteroneMolecular BiologyIncubationCells CulturedFetusbiologyDose-Response Relationship DrugSubstrate (chemistry)Cell BiologyFetal BloodIn vitroCulture MediaSteroid hormoneEndocrinologyBloodchemistryCell cultureSteroid Hydroxylasesbiology.proteinMolecular MedicineSteroid 11-beta-HydroxylaseThe Journal of steroid biochemistry and molecular biology
researchProduct

Splenic Marginal Zone Lymphoma: French Registries Population-Based Treatment and Survival Analyses (2002-2014)

2020

Background. Splenic Marginal Zone Lymphoma (SMZL) is a rare indolent B-cell lymphoma characterized by a massive splenomegaly and a moderate lymphocytosis. There is no standard of care for SMZL so far. The treatment is indicated if constitutional symptoms, massive splenomegaly and/or cytopenia, after a watch and wait period that is highly variable. Rituximab with or without chemotherapy, chemotherapy, and splenectomy are valid treatment approaches. Our objectives were to describe the characteristics of the patients with SMZL retrospectively collected from a French population database, to analyze the treatments received in first line (Tt1) and in second line (Tt2) in term of efficacy, and to …

medicine.medical_specialtyCytopeniaLymphocytosisbusiness.industryConstitutional symptomsmedicine.medical_treatmentImmunologySplenectomyCell BiologyHematologymedicine.diseaseBiochemistryLymphomaInternal medicinemedicineRituximabSplenic marginal zone lymphomaStage (cooking)medicine.symptombusinessmedicine.drugBlood
researchProduct

Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpnsg-0212 Trial (NCT01644110)

2016

Abstract Background: Although ruxolitinib (RUX) reduces constitutional symptoms and splenomegaly in myelofibrosis (MF) therapy options for anemia are limited. In our prior MPNSG-0109 trial of pomalidomide (POM) in MF with cytopenia, anemia responses were reported in 14% and 29% of subjects receiving POM 0.5 mg/d and 2 mg/d, respectively (Schlenk RF et al., ASH 2013, abstract #2822). We designed a phase-Ib/-II combination study of RUX plus POM to evaluate synergistic effects in subjects with anemia and splenomegaly (MPNSG-0212 trial, NCT01644110; Stegelmann et al., ASH 2015, abstract #826). Study Design: Primary endpoints are response rate after 12 treatment cycles (28 days each) according t…

medicine.medical_specialtyCytopeniaRuxolitinibbusiness.industryAnemiaConstitutional symptomsImmunologyCell BiologyHematologyPomalidomidemedicine.diseaseBiochemistrySurgeryTransplantation03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicineCohortMedicineDecompensationbusiness030215 immunologymedicine.drugBlood
researchProduct

Sjøgren's syndrome-associated oxidative stress and mitochondrial dysfunction: Prospects for chemoprevention trials

2012

An involvement of oxidative stress (OS) was found in recent studies of Sjøgren's syndrome (SS) that reported significant changes in protein oxidation, myeloperoxidase activity, TNF-α, nitrotyrosine, and GSH levels in plasma from SS patients. Excess levels of OS markers, as oxidative DNA damage and propanoyl-lysine, were reported in saliva from SS patients. Previous reports concurred with a role of OS in SS pathogenesis, by showing a decreased expression of antioxidant activities in conjunctival epithelial cells of SS patients and in parotid gland tissue samples from SS patients. A link between OS and mitochondrial dysfunction (MDF) is recognized both on the grounds of the established role o…

medicine.medical_specialtyDNA damageMitochondrionBiologyProtein oxidationmedicine.disease_causeChemopreventionBiochemistryPathogenesischemistry.chemical_compoundInternal medicinemedicineHumansSalivaPeroxidasechemistry.chemical_classificationReactive oxygen speciesTumor Necrosis Factor-alphaNitrotyrosineAutoantibodyGeneral MedicineGlutathioneMitochondriaOxidative StressSjogren's SyndromeEndocrinologychemistryTyrosineBiomarkersOxidative stressDNA DamageFree Radical Research
researchProduct